ClinicalTrials.gg
Not yet recruitingNCT06520059OASIS-PRPUpdated Aug 6, 2024

Optimal Articular Solutions With Intraosseous and Synovial Platelet-Rich Plasma

A Phase 4 interventional study of Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration in Knee Osteoarthritis, sponsored by Universidade do Porto. Not yet recruiting at 2 sites in Portugal. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.

Sponsored by Universidade do Porto · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Osteoarthritis, Knee with a site in Portugal — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · Portugal.

Planned enrollment
8th of 11
50 · median 88
Started
2025
with 1 other
Phase 4
Only one
of the 12
Registered
10th of 12
by date
Lead sponsor
1 of 12
Universidade do Porto

Among the 12 studies in Osteoarthritis, Knee with a site in Portugal, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 4, and was the 10th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 12 studies in Osteoarthritis, Knee with a site in Portugal are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Osteoarthritis, Knee with a site in Portugal, or all of them as a file.
02

Study summary

This is a prospective cohort clinical study. Due to logistic constraints at the sites of implementation, a randomized allocation will not be feasible (private clinic). Patients will be selected with the aim of matching for important confounders (sex and age) the grade of knee OA will be restricted to advance stages.

Read the detailed description

A prospective cohort clinical study. The matched sample will be divided into two groups. Group 1 will receive two intraosseous injections of PRP and another intra-articular injection of PRP on the same day.

Group 2 will only receive two intra-articular injections of PRP, separated by one week. One week before the PRP injection, both groups will receive an intra-articular injection of 20 mg triamcinolone hexacetonide.

The PRP is obtained from an autologous blood sample. PRP production consists of a 54 mL (PRP intra-articular) and 80 mL (PRP intraosseous) sample of venous blood from the cubital vein of the patient's upper limb, using 6 x 9 ml tubes, containing a 3.2% sodium citrate solution. The tubes will be centrifuged at 2400 rpm for 12 minutes at room temperature. It is obtained a suspended concentration of PRP that is carefully extracted using a pipette to avoid aspiration of leukocytes from the buffy coat (leukocyte-poor PRP [LP-PRP]). For group 1, it will be injected 4 mL intraosseous, and 8 mL intra-articular. Group 2 will be injected 8 ml of PRP twice (one each week). A total of 8 ml of PRP will be injected into the knee.

A hemogram will be used to analyze the blood sample and the PRP to evaluate their characteristics (concentration of red blood cells, concentration of white blood cells, concentration of platelets, and mean platelet volume); with this analysis, it will be also calculated the platelet concentration growth factor (between baseline blood sample and PRP). Besides concentration, it will also be calculated the total volume of platelets injected into the knee.

All procedures will be carried out in a laminar flow chamber (0.34 m/s) to avoid contamination. Following preparation, the PRP will be injected with the minimum time elapsed since its preparation (maximum 30 minutes).

The PRP is injected after the skin is prepared and draped. If needed, synovial fluid aspiration will be done before injections. With the patient lying in a supine position on the examination table, with the knees fully extended, the PRP intra-articular injection is performed in a sterile manner via a superolateral patellar approach under ultrasound guidance (Logiq E R8, GE Healthcare).

Regarding intraosseous injections, the location and exploration of the joint line, tibial plateau, and femoral condyle will be done with ultrasound. Following the identification of the articular line through ultrasound examination, the two insertion points for the intraosseous infiltrations in the knee are marked: 2 cm below the tibiofemoral joint line for the tibial plateau and 2 cm above the tibiofemoral joint line for the femoral condyle. The procedure is done for the affected knee compartment (medial or lateral).

To ensure effective and safe analgesia during the intraosseous infiltration procedure, a solution of 1% lidocaine (10 mg/mL). In summary, a 10 mL syringe will be filled with the previously mentioned specified solution and then injected at the marked points-the tibial plateau and femoral condyle. Approximately 4-5 mL will be injected along the path until contact is made with the periosteum, where the trocar will be inserted. An additional 4-5 mL will be injected after the insertion of the trocar. A 10-20 minute time interval will be observed before proceeding with the intraosseous infiltrations. The tibial plateau and femoral condyle will be targeted, and a 15-G trocar-biopsy needle system (1.8 mm diameter, 90 mm length, Arrow OnControl Aspiration needle set, Teleflex Medical Europe Ltd., Dublin, Ireland) will be placed on the tibial and condyle entry mark points. Subsequently, the trocar will be attached to a power driver (Arrow OnControl Powered Bone Access System, Teleflex Medical Europe Ltd., Dublin, Ireland) encased in a sterile plastic sleeve. The trocar will be advanced with precision while its placement is verified using ultrasound imaging. It will be positioned 2 cm below the articular line at a 45-degree angle in the tibial plateau, and 2 cm above the articular line at a 30-degree angle, penetrating 1.5-2 cm into the bone. Accurate depth measurement is made with laser marks on the trocar, spaced 1 cm apart. Once the correct position is confirmed, the power driver will be detached, and the needle core removed. Afterward, 6 mL of activated PRP will be injected through the trocar. Following the injection, the needle core will be reinserted and reattached to the power driver, and the trocar will be withdrawn. Intraosseous infiltration will be consistently performed at the same site in all procedures, as PRP is expected to distribute uniformly across the subchondral area regardless of tissue lesions.

After injection, patients are allowed to mobilize the knee joint, walk as desired and are instructed to apply ice over the injected area for the next 24-48 hours. Patients will be requested to avoid vigorous activity for a minimum of 10 days and to avoid taking NSAIDs for 7 days after injection. Consumption of acetaminophen (max 3 gm/day) will be allowed in the management of pain during the post-intervention period.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Injections, Intra-Articula;
  • Regenerative Medicine;
  • Cartilage Repair
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult individuals with unilateral or bilateral symptomatic knee OA diagnosis according to the American College of Rheumatology
  • with symptoms for more than 3 months
  • confirmed with radiologic diagnosis (Kellgren-Lawrence grades III or IV).
  • Patients must be able to walk with a painful knee.

Exclusion criteria

Exclusion Criteria:

  • previous history of knee surgery
  • systemic or rheumatic disease
  • diseases
  • use of NSAIDs 3 days prior the injections
  • previous history (last 3 months) of systematic use of
  • or other intra-articular injections in the knee in the past 6 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Intraosseous and intra-articular PRP

    Two intraosseous injections of PRP and another intra-articular injection of PRP on the same day.

    Combination Product: Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration

  • Active comparator
    Intra-articular PRP

    Patients submited to two intra-articular injections of PRP, separated by one week.

    Combination Product: Platelet rich-plasma - PRP - intraosseous and intra-articular admnistration

Interventions

  • Combination productPlatelet rich-plasma - PRP - intraosseous and intra-articular admnistration

    Group 1 will receive two intraosseous injections of PRP and a subsequent/synchronous intra-articular injection of PRP on the same day. Group 2 will only receive two intra-articular injections of PRP, separated by one week.

06

What researchers measure

Primary outcomes

  1. PROM - Knee related Qol

    Knee injury and Osteoarthritis Outcome Score (KOOS) - absolute value from the score (units). Min-Max (0-100) higher scores indicate better outcomes and a higher quality of life related to the knee

    Time frame: baseline, and at follow-up of 3 months, 6 months and 12 months

  2. PROM - PAIN

    Visual analogic Score - PAIN (VAS) -absolute value from the score (units). Min-Max (0-10) higher scores indicate worse outcomes

    Time frame: baseline, and at follow-up of 3 months, 6 months and 12 months

Secondary outcomes

  1. bone marrow edema -MRI

    first scored dichotomous (yes/no)

    Time frame: 1 month prior to the injection; 1 month to one year after intervention

  2. bone marrow edema -MRI

    BME will be classified using the criteria defined in the Whole-Organ Magnetic Resonance Imaging Score (WORMS). Range 0-3 Higher scores mean more medular edema.

    Time frame: 1 month prior to the injection; 1 month to one year after intervention

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — This experimental study is safe for patients and will be carried out according to the principles of the Declaration of Helsinki and the European Union General Data Protection Regulation (GDPR). All data processing will be anonymous.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Jul 2026, 18 months later.

Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 18 months is close to that.

Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 25, 2024
StartEst.
Jan 1, 2025
Primary completionEst.
Jul 31, 2026
CompletionEst.
Oct 31, 2027
Last update
Aug 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06520059
Responsible party
João Rocha Neves (MD, MSC, MPH, PHD, FEBVS, Universidade do Porto) — Principal investigator
First posted
Jul 25, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Jul 31, 2026 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Aug 6, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion